Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

被引：0

作者：

Chai, C. S. ^{[1
]}

Liam, C. K. ^{[2
]}

Pang, Y. K. ^{[2
]}

Kow, K. S. ^{[2
]}

Wong, C. K. ^{[2
]}

Poh, M. E. ^{[2
]}

Tan, J. L. ^{[2
]}

机构：

[1] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Kota Samarahan, Malaysia

[2] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

470P

引用

页数：2

共 50 条

[21] The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients
Sarosi, Veronika
Baliko, Zoltan
Smuk, Gabor
Laszlo, Terezia
Szabo, Mariann
Ruzsics, Istvan
Mezosi, Emese
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 755 - 761
[22] A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors
Zhang, Yong
Ye, Ling
Zhang, Huijun
Chen, Xuehua
Ji, Haiying
Chen, Gang
Zhang, Lu
Zhang, Tenfei
Jin, Meiling
JOURNAL OF THORACIC DISEASE, 2018, 10 (10) : E739 - E743
[23] IMPACT OF TYROSINE KINASE INHIBITOR (TKI) DOSAGE MODIFICATIONS ON PROGRESSION-FREE SURVIVAL (PFS) IN THE TREATMENT OF EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
Carrasquilla, S.
Bi, Y.
Gu, W.
Ayyoub, A.
Fletcher, E. Pfuma
Liu, J.
Ramamoorthy, A.
Shord, S.
Zineh, I.
Madabushi, R.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S21 - S21
[24] Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung
Nose, Naohiro
Uramoto, Hidetaka
Iwata, Teruo
Hanagiri, Takeshi
Yasumoto, Kosei
LUNG CANCER, 2011, 71 (03) : 350 - 355
[25] Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
Park, Sehhoon
Ha, Seunggyun
Lee, Se-Hoon
Paeng, Jin Chul
Keam, Bhumsuk
Kim, Tae Min
Kim, Dong-Wan
Heo, Dae Seog
PLOS ONE, 2018, 13 (01):
[26] Long Progression Free Survival and Overall Survival in Advanced NSCLC Patients with EGFR Mutation and Complete Response with TKI Treatment
Macedo-Perez, O.
Lyra-Gonzalez, I.
Marroquin-Flores, D.
Cruz-Rico, G.
Ramirez-Tirado, L.
Valdez-Rojas, L.
Tabares-Nanez, A.
Gonzales-Nogales, J.
Arrieta, O.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2087 - S2087
[27] Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR-Mutated Lung Cancer
Haratake, Naoki
Misumi, Toshihiro
Yamanaka, Takeharu
Seto, Takashi
JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
[28] Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung.
Hussain, S
Zakowski, MF
Kris, MG
Ladanyi, M
Pao, W
Riely, G
Rizvi, N
Gomez, JE
Miller, V
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
[29] Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
Nicos, Marcin
Wojas-Krawczyk, Kamila
Krawczyk, Pawel
Chmielewska, Izabela
Wojcik-Superczynska, Magdalena
Reszka, Katarzyna
Kieszko, Robert
Gora-Florek, Anna
Dudek, Malgorzata
Swiniuch, Daria
Papiewski, Wojciech
Calka, Paulina
Ciesielka, Marzanna
Ramlau, Rodryg
Milanowski, Janusz
ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (06) : 1496 - 1500
[30] Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation
Tanaka, Midori
Ishii, Hidenobu
Moribuchi, Hayato
Naito, Yoshiko
Matsuo, Norikazu
Nakamura, Masayuki
Tokito, Takaaki
Azuma, Koichi
Yamada, Kazuhiko
Hoshino, Tomoaki
INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 715 - 717

← 1 2 3 4 5 →